Osiris Therapeutics, Inc. (OSIR)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 8.30 / 19.30
Exchange NASDAQ
Div & Yield N.A. (N.A)
Osiris Therapeutics To Present At The 25th Annual Piper Jaffray Healthcare Conference

Osiris Therapeutics To Present At The 25th Annual Piper Jaffray Healthcare Conference

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in orthopedic, sports medicine and wound care markets, announced today that C.

Osiris Therapeutics To Present At The Canaccord Genuity Medical Technology And Diagnostics Forum

Osiris Therapeutics To Present At The Canaccord Genuity Medical Technology And Diagnostics Forum

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in orthopedic, sports medicine and wound care markets, announced today that C.

Osiris Therapeutics Inc. Stock Downgraded (OSIR)

Osiris Therapeutics Inc. Stock Downgraded (OSIR)

Osiris Therapeutics (Nasdaq:OSIR) has been downgraded by TheStreet Ratings from from a hold to sell.

Osiris Reports 3rd Quarter 2013 Results: Revenue Up 220%, Strong Balance Sheet, Profitable And Now Cash Flow Positive From Continuing Operations

Osiris Reports 3rd Quarter 2013 Results: Revenue Up 220%, Strong Balance Sheet, Profitable And Now Cash Flow Positive From Continuing Operations

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products in orthopedic, sports medicine and wound care markets announced today its financial results ...

Ratings Changes Today

Upgrades: BAH, BXMT, CDI, EDGW, LIWA, SEE Downgrades: AEGN, ELGX, HWKN, OI, OSIR, PGTI, SLRC, VSH, YELP Initiations: KRFT Read on to get TheStreet Quant Ratings' detailed report:

Osiris Corrects Certain Inaccuracies In Media Reports

Osiris Corrects Certain Inaccuracies In Media Reports

Osiris Therapeutics, Inc. (NASDAQ: OSIR), issued a statement today correcting certain inaccuracies in media reports following the announcement of its favorable agreement with the United States Food and Drug...

FDA Slaps Osiris For Misleading Medical Claims About Stem-Cell Bandage (Update 1)

FDA Slaps Osiris For Misleading Medical Claims About Stem-Cell Bandage (Update 1)

Osiris can no longer claim Grafix treats diabetic foot ulcers and must now submit the bandage to FDA for approval.

Osiris Therapeutics Announces Third Quarter 2013 Financial Results Conference Call

Osiris Therapeutics Announces Third Quarter 2013 Financial Results Conference Call

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for the third quarter ended September 30, 2013, on Friday, November 1, 2013.

Osiris Therapeutics Is Now Oversold (OSIR)

Osiris Therapeutics Is Now Oversold (OSIR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Osiris Legal Team Responds To False And Misleading Story By TheStreet.com

Osiris Legal Team Responds To False And Misleading Story By TheStreet.com

Earlier today, Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced that it has reached agreement with the United States Food and Drug Administration (FDA) regarding the regulatory pathway for its Biosurgery products,...

Osiris And FDA Reach Agreement On Regulatory Pathway For Biosurgery Products

Osiris And FDA Reach Agreement On Regulatory Pathway For Biosurgery Products

Osiris Therapeutics, Inc. (NASDAQ:OSIR), announced today that it has reached agreement with the United States Food and Drug Administration (FDA) regarding the regulatory pathway for its Biosurgery products, ...

Osiris Announces Agreement For Culture-Expanded MSCs Including Prochymal Worth Up To $100 Million Plus Royalties

Osiris Announces Agreement For Culture-Expanded MSCs Including Prochymal Worth Up To $100 Million Plus Royalties

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that it has entered into an agreement with a wholly-owned subsidiary of Mesoblast Limited (ASX:MSB; USOTC:MBLTY) for the sale of Osiris’ culture-expanded...

Grafix® Featured In Multiple Abstracts At The 2013 Fall Symposium On Advanced Wound Care

Grafix® Featured In Multiple Abstracts At The 2013 Fall Symposium On Advanced Wound Care

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that data from seven studies will be presented at the 2013 Fall Symposium on Advanced Wound Care (SAWC) in Las Vegas.

Osiris Accepted For Paper Presentation At The 2014 American Academy Of Orthopaedic Surgeons Annual Meeting

Osiris Accepted For Paper Presentation At The 2014 American Academy Of Orthopaedic Surgeons Annual Meeting

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that a scientific study evaluating the key attributes of Cartiform ® has been accepted for presentation at the 2014 American Academy of Orthopaedic ...

Osiris Therapeutics Stock Sees Short Interest Jump 19.2%

Osiris Therapeutics Stock Sees Short Interest Jump 19.2%

The most recent short interest data has been released by the NASDAQ for the 08/30/2013 settlement date, which shows a 456,303 share increase in total short interest for Osiris Therapeutics Inc , to 2,826,695, an increase of 19.25% since 08/15/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Biotech Stock Mailbag: Merrimack, Rockwell, Prosensa, Osiris

Biotech Stock Mailbag: Merrimack, Rockwell, Prosensa, Osiris

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Grafix® Diabetic Foot Ulcer Clinical Trial Accepted For Presentation At The 2013 Symposium On Advanced Wound Care

Grafix® Diabetic Foot Ulcer Clinical Trial Accepted For Presentation At The 2013 Symposium On Advanced Wound Care

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that its multi-center, randomized, controlled clinical trial evaluating the safety and effectiveness of Grafix ® for the treatment of chronic...

Biotech Stock Mailbag: MannKind, Osiris, BioCryst, Vical, Amarin

Biotech Stock Mailbag: MannKind, Osiris, BioCryst, Vical, Amarin

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

4 Biotech Stocks Rising on Unusual Volume

4 Biotech Stocks Rising on Unusual Volume

Keep these big-volume biotech stocks on your radar.

Dr. Stockstalker

How I Learned to Stop Worrying and Love Market Correction.

Grafix® Demonstrates Overwhelming Efficacy In Landmark Stem Cell Study For The Treatment Of Diabetic Foot Ulcers

Grafix® Demonstrates Overwhelming Efficacy In Landmark Stem Cell Study For The Treatment Of Diabetic Foot Ulcers

Osiris Therapeutics, Inc. (NASDAQ: OSIR), reported today that its multi-center, randomized, controlled clinical trial comparing the safety and effectiveness of Grafix® to standard of care in patients with ...

Osiris Therapeutics Schedules Conference Call To Provide Update On Its Grafix® Diabetic Foot Ulcer Trial

Osiris Therapeutics Schedules Conference Call To Provide Update On Its Grafix® Diabetic Foot Ulcer Trial

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that C.

Osiris Therapeutics Announces Second Quarter 2013 Financial Results

Osiris Therapeutics Announces Second Quarter 2013 Financial Results

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, ...

Osiris Therapeutics Announces Second Quarter 2013 Financial Results Conference Call

Osiris Therapeutics Announces Second Quarter 2013 Financial Results Conference Call

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for the second quarter ended June 30, 2013, on Monday, August 5, 2013.

4 Stocks Rising on Unusual Volume

4 Stocks Rising on Unusual Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Commit To Buy Osiris Therapeutics At $7.50, Earn 13.1% Annualized

Commit To Buy Osiris Therapeutics At $7.50, Earn 13.1% Annualized

Investors considering a purchase of Osiris Therapeutics Inc stock, but cautious about paying the going market price of $10.23/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $7.50 strike, which has a bid at the time of this writing of 40 cents.

Osiris CEO: Our Stem Cell Drug With Zero Sales Is Widely Used

Osiris CEO: Our Stem Cell Drug With Zero Sales Is Widely Used

Osiris CEO claims Prochymal is most widely used stem cell drug in world yet has generated no sales -- ever.

Osiris Therapeutics Inc. Stock Upgraded (OSIR)

Osiris Therapeutics Inc. Stock Upgraded (OSIR)

Osiris Therapeutics (Nasdaq:OSIR) has been upgraded by TheStreet Ratings from a sell to hold.

Osiris Therapeutics To Present At The Canaccord Genuity Musculoskeletal Conference

Osiris Therapeutics To Present At The Canaccord Genuity Musculoskeletal Conference

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, ...